-
Posted by
Two Blokes Jul 11 -
Filed in
Stock
-
8 views
Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman's echocardiography image platform in the People's Republic of China including the Special Administrative Regions of Hong Kong and Macao (the “Territory”). Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. The subsidiary has a GMP certified manufacturing facility in China that is able to produce at a scale capable of addressing the Chinese market.
